About us

Thuja Capital Management (“Thuja Capital”) is an independent venture capital management firm specialized in investing in early-stage medical product companies in the Netherlands and Belgium. With our office in Utrecht Science Park, close to Utrecht University and University Medical Center Utrecht, we are conveniently located in the heart of the Netherlands, at a one-hour driving distance from Belgium.

Healthcare spending has been rising steadily over the last decades, and is expected to continue to grow, due to increased access to healthcare in the developing countries, the aging population and novel technologies. Although the progress in medicine has been phenomenal during the last century, there are still a large number of unmet medical needs.

The Benelux region is at the forefront of life sciences research, yet conversion into medical products has been lagging behind. It is the ambition of Thuja Capital to leverage good science with entrepreneurship and capital, in order to accelerate innovative, affordable medical products to patients, thus pairing societal return to attractive financial reward for its shareholders.

The team of Thuja Capital has a long-standing and successful track record in investments in, and management of, medical product companies.

Thuja Capital takes a unique position: it is the only independent medical product VC with an investment focus on the Benelux. Moreover, we are among the declining number of VCs that invest at a truly early stage.

In addition to capital investments we leverage our extensive network, advisory board and our own experience to help and turn good science into valuable innovative medical products. We believe that we should work closely with our portfolio companies and provide hands-on support. By taking an active role, Thuja Capital aims to help these companies to strengthen and grow their businesses. The central location of our office warrants that we are always within short travelling distance.

Thuja Capital: investing in early stage medical products for diagnosis, cure, care or prevention, that have a true impact

28 November 2017, Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. Read further …

3 October 2017, Nijmegen, The Netherlands – Mellon Medical, a Dutch MedTech developer of a platform technology for suturing with one hand, has raised € 6 million to advance its patented ground breaking global innovation in suturing technology. Read further …

18 September 2017 – A clinical study demonstrating the excellent efficacy and compliance of the Sleep Position Trainer, NightBalance’ revolutionary device to treat positional sleep apnea, has been accepted for publication in the professional journal Sleep and Breathing. Read further …